A New Panel-Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population
Lesley A Inker,Sara J Couture,Hocine Tighiouart,Alison G Abraham,Gerald J Beck,Harold I Feldman,Tom Greene,Vilmundur Gudnason,Amy B Karger,John H Eckfeldt,Bertram L Kasiske,Michael Mauer,Gerjan Navis,Emilio D Poggio,Peter Rossing,Michael G Shlipak,Andrew S Levey,CKD-EPI GFR Collaborators,Margret B Andresdottir,Hrefna Gudmundsdottir,Olafur S Indridason,Runolfur Palsson,Paul Kimmel,Matt Weir,Roberto Kalil,Todd Pesavento,Anna Porter,Jonathan Taliercio,Chi-Yuan Hsu,Jing Chen,Steef Sinkeler,Christina Wyatt,Zipporah Krishnasami,James Hellinger,Joseph Margolick,Lawrence Kingsley,Mallory Witt,Steven Wolinsky,Tariq Shafi,Wendy Post,Alessandro Doria,Hans-Henrik Parving
DOI: https://doi.org/10.1053/j.ajkd.2020.11.005
Abstract:Rationale and objective: Glomerular filtration rate (GFR) estimation based on creatinine and cystatin C (eGFRcr-cys) is more accurate than estimated GFR (eGFR) based on creatinine or cystatin C alone (eGFRcr or eGFRcys, respectively), but the inclusion of creatinine in eGFRcr-cys requires specification of a person's race. β2-Microglobulin (B2M) and β-trace protein (BTP) are alternative filtration markers that appear to be less influenced by race than creatinine is. Study design: Study of diagnostic test accuracy. Setting and participants: Development in a pooled population of 7 studies with 5,017 participants with and without chronic kidney disease. External validation in a pooled population of 7 other studies with 2,245 participants. Tests compared: Panel eGFR using B2M and BTP in addition to cystatin C (3-marker panel) or creatinine and cystatin C (4-marker panel) with and without age and sex or race. Outcomes: GFR measured as the urinary clearance of iothalamate, plasma clearance of iohexol, or plasma clearance of [51Cr]EDTA. Results: Mean measured GFRs were 58.1 and 83.2 mL/min/1.73 m2, and the proportions of Black participants were 38.6% and 24.0%, in the development and validation populations, respectively. In development, addition of age and sex improved the performance of all equations compared with equations without age and sex, but addition of race did not further improve the performance. In validation, the 4-marker panels were more accurate than the 3-marker panels (P < 0.001). The 3-marker panel without race was more accurate than eGFRcys (percentage of estimates greater than 30% different from measured GFR [1 - P30] of 15.6% vs 17.4%; P = 0.01), and the 4-marker panel without race was as accurate as eGFRcr-cys (1 - P30 of 8.6% vs 9.4%; P = 0.2). Results were generally consistent across subgroups. Limitations: No representation of participants with severe comorbid illness and from geographic areas outside of North America and Europe. Conclusions: The 4-marker panel eGFR is as accurate as eGFRcr-cys without requiring specification of race. A more accurate race-free eGFR could be an important advance.